Evidence map›Paper›PMID 39466775›Full record

ArticleCell reports2024

Nanoparticle-based itaconate treatment recapitulates low-cholesterol/low-fat diet-induced atherosclerotic plaque resolution.

Natalie E Hong, Alice Chaplin, Lin Di, Anastasia Ravodina, Graham H Bevan, Huiyun Gao, Courteney Asase, Roopesh Singh Gangwar, Mark J Cameron, Matthew Mignery and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Natalie E HongCardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Biomedical Engineering, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Alice ChaplinCardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Lin DiCardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Biomedical Engineering, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Anastasia RavodinaCardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Graham H BevanCardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Huiyun GaoCardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Courteney AsaseCardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Roopesh Singh GangwarCardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Division of Allergy and Immunology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Mark J CameronDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.
Matthew MigneryCardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Olga CherepanovaDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Aloke V FinnDepartment of Internal Medicine, Cardiovascular Division, University of Maryland School of Medicine, Baltimore, MD, USA; CVPath Institute, Inc., Gaithersburg, MD, USA.
Lalitha NayakCardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Hematology & Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Andrew A PieperDepartment of Psychiatry, Case Western Reserve University, Cleveland, OH, USA; Brain Health Medicines Center, Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Geriatric Psychiatry, GRECC, Louis Stokes VA Medical Center, Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Department of Neurosciences, Case Western Reserve University, Cleveland, OH, USA.
Andrei MaiseyeuCardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. Electronic address: axm1079@case.edu.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · CASE WESTERN RESERVE UNIVERSITY · 1985 to 2005
$7.3M
Medical Scientist Training Program at Case Western Reserve UniversityT32GM152319 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · 2024 to 2025
$3.4M
NHLBI NIH HHS R01 HL130516NHLBI NIH HHS R01 HL155450NIGMS NIH HHS T32 GM007250NIGMS NIH HHS T32 GM152319
6 · The paper itself

Abstract

Current pharmacologic treatments for atherosclerosis do not completely protect patients; additional protection can be achieved by dietary modifications, such as a low-cholesterol/low-fat diet (LCLFD), that mediate plaque stabilization and inflammation reduction. However, this lifestyle modification can be challenging for patients. Unfortunately, incomplete understanding of the underlying mechanisms has thwarted efforts to mimic the protective effects of a LCLFD. Here, we report that the tricarboxylic acid cycle intermediate itaconate (ITA), produced by plaque macrophages, is key to diet-induced plaque resolution. ITA is produced by immunoresponsive gene 1 (IRG1), which we observe is highly elevated in myeloid cells of vulnerable plaques and absent from early or stable plaques in mice and humans. We additionally report development of an ITA-conjugated lipid nanoparticle that accumulates in plaque and bone marrow myeloid cells, epigenetically reduces inflammation via H3K27ac deacetylation, and reproduces the therapeutic effects of LCLFD-induced plaque resolution in multiple atherosclerosis models.

Indexed as

Mice, Inbred C57BLNanoparticlesPlaque, AtheroscleroticSuccinatesAnimalsAtherosclerosisDiet, Fat-RestrictedHumansHydro-LyasesInflammationMacrophagesMaleMiceAcod1 protein, mouseHydro-Lyasesitaconic acidSuccinatesApoE(−/−) miceatherosclerosischolesterolCP: Immunologyitaconatenanoparticleplaque resolutionTCA cycle

Identifiers

PMID39466775
PMCPMC11648168

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.